PD66-08 BCG UNRESPONSIVE DEFINITION SUPERSEDES DISTINCTION BETWEEN REFRACTORY AND RELAPSING DISEASE (2018)

You have accessJournal of UrologyBladder Cancer: Non-invasive III1 Apr 2018PD66-08 BCG UNRESPONSIVE DEFINITION SUPERSEDES DISTINCTION BETWEEN REFRACTORY AND RELAPSING DISEASE Roger Li, William Tabayoyong, Charles Guo, Graciela Nogueras Gonzalez, Neema Navai, H. Barton Grossman, Colin Dinney, and Ashish Kamat Roger LiRoger Li More articles by this author , William TabayoyongWilliam Tabayoyong More articles by this author , Charles GuoCharles Guo More articles by this author , Graciela Nogueras GonzalezGraciela Nogueras Gonzalez More articles by this author , Neema NavaiNeema Navai More articles by this author , H. Barton GrossmanH. Barton Grossman More articles by this author , Colin DinneyColin Dinney More articles by this author , and Ashish KamatAshish Kamat More articles by this author View All Author Informationhttps://doi.org/10.1016/j.juro.2018.02.3004AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookTwitterLinked InEmail INTRODUCTION AND OBJECTIVES BCG unresponsive bladder cancer has been sub-classified as refractory (persistent HG disease at 6 months) and relapsing (recurrent HG disease after achieving disease-free state at 6 months). The oncologic outcomes of the two subcategories following BCG unresponsive designation have not been compared. METHODS We performed an IRB approved review of our bladder cancer database. Overall, 60 BCG refractory unresponsive and 32 relapsing unresponsive patients were identified. Salvage therapy was rendered at the discretion of the treating physician. Baseline clinicopathologic characteristics including age, gender, primary tumor grade, stage, size, multiplicity and concurrent CIS were collected and compared between the two groups. Recurrence free survival (RFS), progression free survival (PFS; with progression defined as the development of MIBC/distant metastasis), cystectomy free survival (CFS) and cancer specific survival (CSS) were compared. All tests were two-sided and p<0.05 was considered statistically significant. RESULTS Baseline clinicopathologic features including age (p=0.45), tumor grade (p=0.66), stage (p=0.14), concurrent CIS (p=0.18), and tumor multiplicity (p=0.38) were similar between the two groups. On KM analysis, patients with BCG refractory and relapsing disease demonstrated similar RFS (Median 8mo, 95% CI 5-19mo vs. 14mo, 95% CI 4-33mo, p=0.97) (Fig. 1a), PFS (Median NR vs. 74mo, 95% CI 38mo-NE, p=0.95), CFS (Median NR vs. 27mo, 95% CI 14-61mo, p=0.19) and CSS (Median NR vs. NR, p=0.73). On univariate and multivariate analyses, BCG refractory and relapsing unresponsive disease were not found to independently predict RFS, PFS, CFS, or CSS. CONCLUSIONS When strictly abiding by the definition of BCG unresponsive disease, BCG refractory unresponsive and BCG relapsing unresponsive patients had similar RFS, PFS, CFS, and CSS. © 2018FiguresReferencesRelatedDetails Volume 199Issue 4SApril 2018Page: e1233 Advertisement Copyright & Permissions© 2018MetricsAuthor Information Roger Li More articles by this author William Tabayoyong More articles by this author Charles Guo More articles by this author Graciela Nogueras Gonzalez More articles by this author Neema Navai More articles by this author H. Barton Grossman More articles by this author Colin Dinney More articles by this author Ashish Kamat More articles by this author Expand All Advertisement Advertisement PDF downloadLoading ...